Topical Diabetic Neuropathy Gel Enters Phase 3

| Dec 20, 2013

Clonidine, a topical gel designed for the treatment of painful diabetic neuropathy, will begin phase three studies early in 2014 after its maker, North Carolina-based BioDelivery Sciences International, Inc., garnered fast-track approval from the Food and Drug Administration for the trials.

As it continues to assess the effectiveness and safety of the drug, BDSI will include two placebo-controlled studies along with one study on the safety of the drug for those suffering from diabetic neuropathy in its upcoming research.

"As we continue our work to expand and diversify our product pipeline, we are very pleased with the outcome of our discussion with FDA regarding the development program for Clonidine Topical Gel," said Dr. Andrew Finn, Executive Vice President of Product Development at BDSI, said that the FDA had granted Fast Track designation for the drug, an indicator "that the FDA recognizes the need for new treatment options for diabetic neuropathy that could potentially lead to a priority review."

BDSI met with representatives of the FDA on Nov. 21 to discuss the proposed Phase 3 clinical process. If the results of the first placebo-controlled studies are as expected, the company could initiate second studies in 2015, allowing the gel to reach the marketplace by 2016.

Clonidine gel is believed to relieve the pain of diabetic peripheral neuropathy-an often debilitating side effect of diabetes that can severely impact quality of life for sufferers-by decreasing the abnormal hyper-excitability of nerve cells, slowing the cells' response to pain stimuli.

It works differently than the oral medications currently on the market used to treat neuropathy, and would be the only topical product approved for the treatment of this painful condition.

Many of the nearly 26 million people in the U.S. who have diabetes, according to the American Diabetes Association, suffer from neuropathy, which creates tingling, burning, or stabbing pains in the feet, a result of damaged nerves.

BDSI estimates the annual sales potential of Clonidine to be in excess of $300 million.

 

Click Here To View Or Post Comments

Categories: BDSI, BioDelivery Sciences International, Clonidine, Diabetic Neuropathy


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.